Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Stock Up 1.9 %

Shares of NASDAQ EVGN opened at $1.57 on Wednesday. The stock has a market capitalization of $8.43 million, a P/E ratio of -0.35 and a beta of 1.30. The firm’s 50-day moving average price is $1.59 and its two-hundred day moving average price is $2.67. Evogene has a 52-week low of $1.20 and a 52-week high of $10.40.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) EPS for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.